| HOME >> BIOLOGY >> TECHNOLOGY |
Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals,
Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences,
Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics LLC.
ISIS PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidated Statements of Operations
(In Thousands, Except Per Share Data)
Three months ended, Six months ended,
June 30, June 30,
2008 2007 2008 2007
Revenue: (unaudited) (unaudited)
Research and development revenue
under collaborative agreements $26,814 $3,482 $47,499 $5,484
Licensing and royalty revenue 6,147 331 6,815 779
Total revenue 32,961 3,813 54,314 6,263
Expenses:
Research and development 31,195 20,384 57,642 40,333
Selling, general and
administrative 4,899 3,089 8,635 6,491
Total operating expenses 36,094 23,473 66,277 46,824
Loss from operations (3,133) (19,660) (11,963) (40,561)
Other income (expense):
Investment income 560 3,053 5,515 6,454
Interest expense (1,391) (2,016) (2,788) (4,644)
Gain on investments, net - 1,989 - 3,510
Loss on early retirement of debt - (1,993) - (3,212)
Loss attributed to noncontrolling
interest in Symphony GenIsis, Inc. - 7,60
'/>"/>
| SOURCE Isis Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |